Dominika Gieroba

Dominika Gieroba

Auto-generated profile, based on publicly available information

Dominika Gieroba

Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
WWWiktor Werenkowicz
Wiktor Werenkowicz
AAAngelika Adamczyk-Werenkowicz
Angelika Adamczyk-Werenkowicz
TWTomasz Wiśniewski
Tomasz Wiśniewski
ZKZofia Kosztyła-Czech
Zofia Kosztyła-Czech
AMAnna Mazur
Anna Mazur
KKKamila Kapłon
Kamila Kapłon
Introduction and purpose: Articular cartilage lesions represent a major clinical problem because of the cartilage's limited self-healing capability. In this regard, current regenerative medicine approaches emphasize stem cell-based strategies, especially those that employ MSCs, as a hopeful approach toward the repair of cartilage lesions. This review aims to provide an updated synthesis of current strategies, including cellular mechanisms, delivery techniques, and clinical outcomes, with a focus on optimizing MSC-based interventions. A brief description of the state of knowledge: MSCs from different tissues, such as bone marrow, adipose tissue, synovium, and umbilical cord, manifest dissimilar biological behaviours, which influence their therapeutic performances. They promote the repair of damaged cartilage by direct differentiation, immunomodulatory effects, and paracrine signalling. Delivery systems, like intra-articular injections and scaffold-based methods, are being refined to enhance MSC retention, viability, and integration. Preclinical models confirm their regenerative capacity, while early clinical trials have shown safety and functional improvement. However, cell heterogeneity, hypertrophic differentiation, and inflammatory environments in joints are some issues yet to be overcome. Conclusions: Stem cell therapies, with MSCs in particular, hold immense potential for the regeneration of articular cartilage. Although present results are encouraging, additional studies should be conducted to standardize treatment protocols, improve cell sources and delivery systems, and establish long-term clinical efficacy.

9 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
ŻKŻaneta Kania
Żaneta Kania
GKGabriela Kapłon
Gabriela Kapłon
KGKarolina Glajcar
Karolina Glajcar
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and constitutes a significant public health concern due to its rising incidence and the absence of curative therapies. This review synthesizes recent pharmacological progress in the treatment of AD, with particular emphasis on emerging therapeutic strategies and investigational drug classes. The analysis draws on clinical trial data, regulatory documents, and peer-reviewed literature published between 2017 and 2025, identified through major scientific databases including PubMed, Scopus, and ClinicalTrials.gov. The most promising advances are associated with monoclonal antibodies directed against amyloid-beta pathology, such as aducanumab, lecanemab, and donanemab, which show potential to modify disease progression but also raise concerns related to efficacy, safety, and regulatory approval. Additional innovative approaches, including tau-targeted therapies, gene editing technologies such as CRISPR-Cas9, and RNA interference (RNAi), present new therapeutic opportunities, though they remain limited by challenges such as amyloid-related imaging abnormalities (ARIA), restricted delivery across the blood–brain barrier, and uncertainties regarding long-term clinical outcomes. While currently available pharmacological options are insufficient to halt or reverse AD, recent advancements, particularly in antibody-based therapies, represent an important step toward a new therapeutic era. Nevertheless, cautious interpretation of preliminary findings and rigorous clinical validation remain essential before these strategies can be translated into widespread clinical practice.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DGDominika Gieroba
Dominika Gieroba
AKAnna Kamieniak
Anna Kamieniak
WPWeronika Perczyńska
Weronika Perczyńska
GKGabriela Kapłon
Gabriela Kapłon
JSJulia Szczotka
Julia Szczotka
KGKarolina Glajcar
Karolina Glajcar
Research objectives: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a complex pathogenesis in which the brain-gut axis is disrupted. Due to the multifactorial basis of the disorder, it is very important to combine pharmacological and psychological treatment with dietary treatment to alleviate patients' symptoms. The purpose of this dissertation was to present the effectiveness of pharmacological, dietary, psychological and novel treatments currently at research level in patients with irritable bowel syndrome. Method: In order to evaluate the effectiveness of various therapies in IBS, a systematic review was conducted. It covers articles from years 2020 - 2024, that were published in PubMed, MDPI, and Sage Journals databases. Key Findings: The treatment of irritable bowel syndrome requires a combination of different therapies to achieve an effective therapeutic effect. There is no specific form of treatment to cure IBS. Conclusions: Currently it is only possible to alleviate the discomfort and improve the quality of life by combining the various methods available. The method that seems to be the most effective is a combination of pharmacological, dietary and psychological treatment. Pharmacological therapy makes it possible to alleviate pain, constipation or diarrhea. The introduction of the FODMAP diet eliminates factors that adversely affect the intestinal microbiota, and psychotherapy, combined with pharmacological treatment of depression and anxiety, alters thinking and synthesizes hormones that affect the gut-brain axis. Alternative treatments are currently being researched, but it will take time and further research before these methods can be incorporated into standard therapy.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
MCMarianna Chmiel
Marianna Chmiel
Background: Hashimoto’s thyroiditis is one of the most common autoimmune diseases, with a noticeable increase in incidence observed in recent years. Despite its high prevalence, current treatment options remain limited and primarily focus on managing the consequences rather than addressing the underlying causes of the condition. Metformin, although primarily prescribed for diabetes, has demonstrated promising anti-inflammatory and immunoregulatory properties in several autoimmune disease models. Aim: This review aims to evaluate the potential role of metformin in the management of Hashimoto’s thyroiditis, with a particular focus on its effects on immune regulation and thyroid function. Methods: An electronic literature search was performed using PubMed, Cochrane Library, ScienceDirect and Evidence‑Based Medicine Reviews. Search terms included ‘Metformin’, ‘Hashimoto disease’, ‘Thyroiditis’, ‘Thyroid’, ‘autoimmune disease’ as keywords. Only articles in English were considered. Conclusions: Preliminary data suggest that metformin, through its anti-inflammatory properties and modulation of AMPK/mTOR pathways, may influence immune responses in Hashimoto’s thyroiditis. Despite promising preclinical findings, further clinical trials involving human participants are required to evaluate its therapeutic efficacy and safety in this context.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MCMarianna Chmiel
Marianna Chmiel
ATArtur Tumiński
Artur Tumiński
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
DGDominika Gieroba
Dominika Gieroba
Introduction and objective: Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that may follow viral infections. We present a case of a 12-month-old boy who developed disseminated intravascular coagulation (DIC) and fulfilled HLH diagnostic criteria following influenza A virus infection. Extensive diagnostics excluded a genetic cause. Treatment based on the HLH-2018 protocol led to full recovery. This case emphasizes the importance of considering HLH in infants with severe systemic inflammation and coagulopathy, even in the absence of EBV infection. Early recognition and appropriate therapy are essential to improve outcomes. Results. This case report describes a 12-month-old boy with haemophagocytic lymphohistiocytosis (HLH) and disseminated intravascular coagulation (DIC) following influenza A infection. Despite negative genetic testing, the patient met HLH diagnostic criteria. Treatment per HLH-2018 protocol was successful. The case underscores the importance of early recognition of HLH in viral infections beyond Epstein-Barr virus.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AKAnna Kamieniak
Anna Kamieniak
DGDominika Gieroba
Dominika Gieroba
Introduction: Type II diabetes is a chronic metabolic disease characterized by hyperglycemia. The goal of diabetes treatment is to achieve normal blood glucose levels and prevent complications arising from diabetes. Currently, there are many groups of antidiabetic drugs available, differing in their main indications for use, mechanism of action, and side effects, which allow the selection of the most effective and best tolerated treatment method for a specific patient. Objective: The objective of this review was to compare the efficacy of drugs used as first-line treatments for type II diabetes, namely metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, also known as flozins, taking into account their limitations and adverse effects. Method: In order to compare the effectiveness of metformin, GLP-1 agonists, and SGLT2 inhibitors in the treatment of type II diabetes, a systematic review was conducted between 2020 and 2025, covering the PubMed database. Key words such as type II diabetes, metformin, GLP-1 receptor agonist, MALA, SGLT2 inhibitors were used. Conclusions: The comparison shows that metformin, GLP-1 agonists, and SGLT2 inhibitors are effective drugs used in the treatment of type II diabetes, and the choice of the appropriate drug depends on the patient's condition, comorbidities, and the desired effects. SGLT2 inhibitors are the best choice for patients with heart failure and renal failure, while GLP-1 agonists are the most suitable for patients with high cardiovascular risk, as they reduce the risk of heart attack or stroke. Metformin, by increasing the sensitivity of peripheral tissues to insulin, is used in the treatment of both diabetes and insulin resistance. In addition, it is the cheapest of the compared groups of drugs, which may be an important aspect in the selection of therapy for individual patients coming from poor environments. All three groups lower blood glucose without the risk of hypoglycemia. Side effects mainly include gastrointestinal disorders (metformin, GLP-1) and urinary tract infections (SGLT2). Summing up the above conclusions, it can be stated that the choice of drug in diabetes therapy should mainly depend on the patient's comorbidities.